Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Testicular Neoplasms 2Neoplasms 2Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Seminoma 1Oropharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Hearing Loss 1Carcinoma 1Anosmia 1Adenocarcinoma 1

Interventions

Cisplatin 8Etoposide 7Carboplatin 7Paclitaxel 6Ifosfamide 6Filgrastim 4pegfilgrastim 2Therapeutics 2Radiotherapy 2Platinum 2Granulocyte Colony-Stimulating Factor 2Bleomycin 2tremelimumab 1sodium thiosulfate 1liposomal amphotericin B 1etoposide phosphate 1durvalumab 1cabozantinib 1Vinblastine 1Thiotepa 1Sunitinib 1Ribavirin 1Psychiatric Rehabilitation 1Peripheral Blood Stem Cell Transplantation 1Palivizumab 1Neoadjuvant Therapy 1Mesna 1Magnetic Resonance Spectroscopy 1Lenograstim 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Seminoma × Hearing × Clear all
NCT07218913 2026-04-17

Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors

City of Hope Medical Center

Phase 1 Recruiting
44 enrolled
Genitourinary

Testicular Neoplasms, Seminoma, Hearing Loss

Data powered by HemOnc (CC BY 4.0) Colophon âš¡